Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Frontier Reports Positive Results from Early Trial of COVID-19 Therapy

publication date: Aug 12, 2022

Nanjing Frontier Biotechnologies announced positive results from a Phase 1 trial of its COVID-19 therapy. FB2001 (bofutrelvir) is a small molecule inhibitor of coronavirus main protease (Mpro) that was tested in healthy adult volunteers. It was found to be safe and well-tolerated in both China and US patients. The IV formulation of FB2001 is intended for hospitalized patients. Frontier has already started a pivotal Phase II/III trial that will enroll 1,200 hospitalized patients in hundreds of clinical centers worldwide. Frontier will also develop a pulmonary formulation of FB2001 for out-patient treatment of mild Covid-19. More details....

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital